Assignee
REVERAGEN BIOPHARMA INC
US·12 granted patents·11 pending applications·52 citations·filing 2012–2025
Top patents by PatentIndex Score
23 records- 0194US11471471B2Aqueous oral pharmaceutical suspension compositionsREVERAGEN BIOPHARMA INC·Filed 2022·Granted Oct 18, 2022·3 cites·21 claims
- 0294US11382922B2Aqueous oral pharmaceutical suspension compositionsREVERAGEN BIOPHARMA INC·Filed 2020·Granted Jul 12, 2022·4 cites·26 claims
- 0393US10799514B2Non-hormonal steroid modulators of NF-kappa beta for treatment of diseaseREVERAGEN BIOPHARMA INC·Filed 2016·Granted Oct 13, 2020·6 cites·18 claims
- 0492US10857161B2Non-hormonal steroid modulators of NF-kB for treatment of diseaseREVERAGEN BIOPHARMA INC·Filed 2018·Granted Dec 8, 2020·6 cites·21 claims
- 0592US10206933B2Non-hormonal steroid modulators of NF-kB for treatment of diseaseREVERAGEN BIOPHARMA INC·Filed 2017·Granted Feb 19, 2019·7 cites·14 claims
- 0692US9649320B2Non-hormonal steroid modulators of NF-κB for treatment of diseaseREVERAGEN BIOPHARMA INC·Filed 2016·Granted May 16, 2017·8 cites·3 claims
- 0791US12201639B2Aqueous oral pharmaceutical suspension compositionsREVERAGEN BIOPHARMA INC·Filed 2022·Granted Jan 21, 2025·1 cites·14 claims
- 0890US9434758B2Non-hormonal steroid modulators of NF-κB for treatment of diseaseREVERAGEN BIOPHARMA INC·Filed 2014·Granted Sep 6, 2016·8 cites·2 claims
- 0988US11833159B2Non-hormonal steroid modulators of NF-kB for treatment of diseaseREVERAGEN BIOPHARMA INC·Filed 2020·Granted Dec 5, 2023·1 cites·12 claims
- 1087US2024285650A1NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASEREVERAGEN BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 1186US11690853B2Non-hormonal steroid modulators of NF-κβ for treatment of diseaseREVERAGEN BIOPHARMA INC·Filed 2020·Granted Jul 4, 2023·1 cites·13 claims
- 1284US2025205251A1Aqueous oral pharmaceutical suspension compositionsREVERAGEN BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 1383US10464967B2Non-hormonal steroid modulators of NF-κβ for treatment of diseaseREVERAGEN BIOPHARMA INC·Filed 2012·Granted Nov 5, 2019·7 cites·4 claims
- 1478US2024307411A1Non-hormonal steroid modulators of nf-kappa beta for treatment of diseaseREVERAGEN BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 1574US2020148717A1Non-hormonal steroid modulators of nf-kappa beta for treatment of diseaseREVERAGEN BIOPHARMA INC·Filed 2019·Application pending·0 cites
- 1672US2024139210A1Treatment of nf-kb-mediated diseaseREVERAGEN BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 1771US2022324902A1Non-hormonal steroid modulators of nf-kappa beta for treatment of diseaseREVERAGEN BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 1869US2025145657A1Non-hormonal steroid modulators of nf-kappa beta for treatment of diseaseREVERAGEN BIOPHARMA INC·Filed 2025·Application pending·0 cites
- 1966US2022184098A1Treatment of nf-kb-mediated diseaseREVERAGEN BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 2066US2024299416A1TREATMENT OF NF-kB-MEDIATED DISEASEREVERAGEN BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 2166US2024226117A1Treatment of congenital adrenal hypoplasiaREVERAGEN BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 2253US10000525B2Non-hormonal steroid modulators of NF-κB for treatment of diseaseREVERAGEN BIOPHARMA INC·Filed 2015·Granted Jun 19, 2018·0 cites·18 claims
- 2350US2023002439A1Crystalline forms of vamoroloneREVERAGEN BIOPHARMA INC·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when REVERAGEN BIOPHARMA INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →